Advertisement

Flumazenil Injection

[01 December 2016]

Products Affected - Description

All presentations are currently available

Reason for the Shortage

  • Fresenius Kabi had flumazenil on shortage due to short-term manufacturing delays.
  • Mylan Institutional could not provide a reason for the shortage.
  • Sandoz discontinued flumazenil injection in 2015.
  • West-Ward states the reason for the shortage is increased demand.

Available Products

Flumazenil injection, Fresenius Kabi
0.1 mg/mL, 5 mL vial, 10 count (NDC 63323-0424-05)
0.1 mg/mL, 10 mL vial, 1 count (NDC 63323-0424-10)
 
Flumazenil injection, Mylan Institutional
0.1 mg/mL, 5 mL vial, 10 count (NDC 67457-0447-53)
0.1 mg/mL, 10 mL vial, 10 count (NDC 67457-0444-10)
 
Flumazenil injection, West-Ward
0.1 mg/mL, 5 mL vial, 10 count (NDC 00143-9784-10)
0.1 mg/mL, 10 mL vial, 10 count (NDC 00143-9783-10)

Estimated Resupply Dates

All marketed presentations are available.

Related Shortages

Updated

December 1, November 9, September 27, July 26, 15 and 7, May 25, January 12, 2016; December 30 and 15, November 30 and 17, October 20, 12 and 2, September 18, August 12, July 28, June 15, 2015, University of Utah, Drug Information Service. Copyright 2016, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins

Advocacy Activity
Get the latest updates on ASHP's advocacy activity on drug shortages.
Advertisement
ASHP Product Listing